ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.692,01
-0,40%
S&P 500
5.308,81
0,01%
Dow Jones
39.849,01
0,11%
Euro vs US Dollar
1,08549
-0,05%
Bitcoin
70.544,96
-1,27%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Achillion Pharmaceuticals Inc (ACHN)

  7. Achillion Pharmaceuticals Inc (ACHN) News

ACHN

Achillion Pharmaceuticals (ACHN)

Achillion Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ACHN
DatumZeitQuelleÜberschriftSymbolFirma
14/02/202022h55Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ACHNAchillion Pharmaceuticals Inc
14/02/202019h29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
12/02/202016h27Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
12/02/202013h58Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
10/02/202013h34Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
07/02/202012h11Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:ACHNAchillion Pharmaceuticals Inc
03/02/202012h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ACHNAchillion Pharmaceuticals Inc
03/02/202012h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ACHNAchillion Pharmaceuticals Inc
03/02/202012h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ACHNAchillion Pharmaceuticals Inc
03/02/202012h00Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ACHNAchillion Pharmaceuticals Inc
19/12/201915h24GlobeNewswire Inc.Achillion Shareholders Approve Agreement to be Acquired by AlexionNASDAQ:ACHNAchillion Pharmaceuticals Inc
09/12/201916h00GlobeNewswire Inc.Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who...NASDAQ:ACHNAchillion Pharmaceuticals Inc
22/11/201916h42PR Newswire (US)Moore Kuehn, PLLC Encourages Investors of SRC Energy, Inc. (SRCI), Achillion Pharmaceuticals, Inc. (ACHN), and Arotech Corpor...NASDAQ:ACHNAchillion Pharmaceuticals Inc
19/11/201913h30GlobeNewswire Inc.European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients...NASDAQ:ACHNAchillion Pharmaceuticals Inc
11/11/201913h30GlobeNewswire Inc.Achillion Announces Clearance of Investigational New Drug Application for ACH-5228NASDAQ:ACHNAchillion Pharmaceuticals Inc
07/11/201922h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACHNAchillion Pharmaceuticals Inc
07/11/201922h18Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
07/11/201922h08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACHNAchillion Pharmaceuticals Inc
07/11/201913h30GlobeNewswire Inc.Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:ACHNAchillion Pharmaceuticals Inc
06/11/201915h07GlobeNewswire Inc.Achillion Announces Data Presentations at the 61st American Society of Hematology Annual MeetingNASDAQ:ACHNAchillion Pharmaceuticals Inc
05/11/201923h07Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (preliminary) (prem14a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
01/11/201921h23Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
18/10/201923h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACHNAchillion Pharmaceuticals Inc
18/10/201922h50PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.NASDAQ:ACHNAchillion Pharmaceuticals Inc
17/10/201923h09Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
16/10/201922h55Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
16/10/201916h44PR Newswire (US)Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Achillion Pharmaceuticals, Inc. has obtained a Fair Price in it...NASDAQ:ACHNAchillion Pharmaceuticals Inc
16/10/201914h54Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACHNAchillion Pharmaceuticals Inc
16/10/201914h52Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ACHNAchillion Pharmaceuticals Inc
16/10/201914h50PR Newswire (US)Achillion (ACHN) Alert: Johnson Fistel Investigates Proposed Sale of Achillion Pharmaceuticals; Are Shareholders Getting a Fa...NASDAQ:ACHNAchillion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACHN

Kürzlich von Ihnen besucht

FX
EURGBP
Euro vs Sterling
TG
CBK
Commerzbank
USOTC
BASFY
BASF (QX)
AMEX
XLF
Financial Select Sector
TG
D7G
Nel ASA
NASDAQ
TSLA
Tesla
NYSE
KO
Coca Cola
NASDAQ
MSFT
Microsoft
TG
432
Arbor Metals
TG
LHA
Deutsche Lufthansa
TG
ALV
Allianz
DBI
SDXP
SDAX
CCOM
US100
US Tech 100
NASDAQ
GOOGL
Alphabet
TG
MBG
MercedesBenz
USOTC
RHHBY
Roche (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten